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ABSTRACT 
Sphingosine- I-Phosphate Inhibits Vascular Smooth Muscle 
Cell Migration by Activating G„iz and RhoA. (April 2004) 
Nicholas J. Anthis 
Department of Biochemistry 
Texas ARM University 
Fellows Advisor: Dr. George E. Davis 
Department of Pathology and Laboratory Medicine 
Angiogenesis, the formation of new blood vessels, is important in growth, 
healing, and disease. Sphingosine-1-phosphate (S1P) is a lysophospholipid with potent 
angiogenic effects. One of these effects is its regulation of cellular migration, an early 
step in angiogenesis. S1P exerts contradictory effects on different types of vascular 
cells, strongly inducing endothelial cell (EC) migration while strongly inhibiting 
vascular smooth muscle cells (VSMC) migration. Here, we demonstrate that S1P 
inhibits the migration of VSMCs by activating G ir and RhoA. SlP abolished the 
migration of VSMCs in response to platelet-derived growth factor (PDGF), a potent 
stimulator of VSMC migration. PDGF strongly induced the formation of lamellipodia, 
which are membrane ruffles associated with cell migration. S1P eliminated these and 
induced the formation of stress fibers, which are actin cytoskeletal structures that 
stabilize the cell. The members of the Rho family of small GTPases regulate 
cytoskeletal morphology and function. Rac 1 induces lamellipodia, RhoA induces stress 
fibers, and Cdc42 induces filopodia, which are small finger-like membrane spikes. We 
introduced dominant-negative (DN) and constitutively active (CA) mutants of the Rho 
GTPases into VSMCs using adenoviral vectors. The results indicated that S1P inhibits 
VSMC migration by activating RhoA. RhoA activation was also demonstrated directly 
using a RhoA pull-down assay. S1P exerts its cellular effects by activating the 
endothelial differentiation gene G-protein-coupled receptors, which initiate signaling 
pathways by activating different G subunits of heterotrimeric G proteins. To determine 
which Ga subunit S1P activates in order to activate RhoA, we introduced DN and CA 
mutants of G tq and G„t3 into VSMCs through adenoviral vectors. The results indicated 
that SIP activates RhoA by activating G &z. These results are important because they 
further elucidate some of the key signaling pathways regulating angiogenesis. When 
angiogenesis begins, ECs migrate in response to SIP and other factors. Interestingly, 
our new data suggest that SIP may prevent VSMCs from interfering with early EC tube 
assembly, by inhibiting VSMC migration through selective activation of G ~2 and RhoA. 
Later, after the ECs have established a network of capillary tubes, they secrete additional 
factors, such as PDGF, which attract VSMCs to them, allowing mature blood vessels to 
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INTRODUCTION 
Angiogenesis, the formation of new blood vessels, is necessary for growth, 
development, and healing. Abnormal angiogenesis, though, is also implicated in many 
pathological conditions. In diabetic retinopathy, uncontrolled angiogenesis occurs in the 
eye, creating leaky vessels that lead to blindness' . Angiogenesis is also implicated in 
atherosclerosis, obesity, psoriasis, as well as ischemic heart and limb disease. Most 
notably, tumors stimulate angiogenesis, which is necessary for their growth'. Although 
angiogenesis is a highly studied topic, the basic molecular mechanisms controlling this 
process are still not well understood. Before abnormal angiogenic conditions can be 
effectively addressed, a clear understanding of factors that both stimulate and inhibit 
angiogenesis is necessary. Sphingosine-1-Phosphate (S1P) has recently emerged as a 
potent regulator of angiogenesis ' . A detailed understanding of the signaling pathways 
it initiates will lead to a much greater understanding of angiogenesis and may offer 
several targets for controlling pathological angiogenesis. 
The basic cellular stages of angiogenesis have been previously determined I 1-15 
Blood vessels, regardless of type or size, all have a similar structure. The inner layer 
consists of endothelial cells, surrounded on the outside by a basement membrane. A 
layer of smooth muscle cells lies on the outside of this basement membrane. 1n larger 
vessels, this layer of smooth muscle cells is surrounded by an additional layer of 
This thesis follows the style and format of Circulation Research. 
connective tissue. Angiogenesis be~us when, in response to a stimulus, a portion of the 
vessel wall breaks down, and endothelial cells migrate away from it. These endothelial 
cells undergo morphogenesis to form capillary tubes. Smooth muscle cells then migrate 
to the new vessels, allowing them to stabilize and mature. 
Many molecules have been characterized that are involved in angiogenesis. One 
of these, which is used in this study is platelet-derived growth factor (PDGF). PDGF is 
a well-characterized protein growth factor, which has a strong chemotactic (i. e. 
attractive) effect on smooth muscle cells' ' . Interestingly, endothelial cells also 
produce PDGF ' . In fact, the production of PDGF is upregulated as ECs undergo 
morphogenesis into capillary tubes ', indicating that it is a key molecule in the later 
stages of angiogenesis, when endothelial and smooth muscle cells communicate to 
achieve vessel maturation. The lipid growth factor S1P has emerged more recently as an 
angiogenic molecule. Its angiogenic effects have been well documented, and the 
molecular means by which it exerts these effects are being elucidated "' . S1P 
stimulates endothelial cell migration ' and induces their morphogenesis into capillary 5, 7 
tube networks ' . In contrast, S1P also inhibits vascular smooth muscle cell migration, 6, IO 8 
emphasizing the importance of S1P in the earlier steps of angiogenesis, where S1P 
allows endothelial cells to migrate and develop while preventing smooth muscle cells 
from interfering with this process. There is still much to learn about the detailed 
molecular signaling pathways that SIP initiates in cells, especially in how they differ 
between cell types. 
S1P, a lysosphingolipid released primarily by activated platelets ', acts on cells 
through the G-protein-coupled endothelial differentiation gene (Edg) receptors, most 
importantly Edgl, Edg3, and Edg5 . The varied effects of S1P on different cell types 
appear to depend on the specific receptors present. Endothelial cells, which express high 
levels of the receptor Edg1, are stimulated to migrate and to invade tissues in the 
presence of S1P. The movement of smooth muscle cells, which express high levels of 
Edg5 and almost no Edgl, is almost completely inhibited by S1P . The roles of the 
various Edg receptors are well established, but only a few details are known about the 
signaling pathways they initiate. Our goal is to further elucidate the molecular means by 
which S1P inhibits smooth muscle cell migration. 
The Rho GTPases — which include Rac 1, Cdc42, and RhoA — maintain a central 
role in cytoskeletal function, which is involved in cell migration . Rac1 induces the 24-26 
formation of lamellipodia, which are actin cytoskeletal structures associated with cell 
migration. Cdc42 induces the formation of filopodia, which are finger-like membrane 
spikes. RhoA induces the formation of stress fibers, stress fibers, which are actin 
cytoskeletal structures that stabilize the cell. These proteins cycle between an active, 
GTP-bound, state and an inactive, GDP-bound state . Another research group has 
already connected Edg5 activation with subsequent Rac 1 inactivation to that may lead to 
inhibition of smooth muscle cell migration by S1P . Although it is likely that Racl 
inactivation may play a role in S1P-mediated inhibition of migration, evidence from our 
laboratory provides new evidence that RhoA activation may play a more central, 
causative role. 
When a ligand, such as S1P, activates a G-protein-coupled receptor, the receptor 
activates a heterotrimeric G-protein. Heterotrimeric G-proteins have three subunits, with 
the G„subunit causing most of the effects of interest . The G, subunit cycles between 
an active, GTP-bound, state and an inactive, GDP-bound, state. There are a few 
different families of G, but the newest family, G„Q/f3 is most relevant here. The 
Gu1 2/13 proteins have been previously shown to activate RhoA . Although the two 
members of this family, G, Iq and G, t3 are often discussed together as performing 
similar functions, we have evidence that they can exert very different effects, especially 
in pathways related to S1P. Much more research is necessary on these molecules and 
the other molecules that couple the Edg receptors to the Rho GTPases. 
My goal is to elucidate the molecular signaling pathways that lead to inhibition 
of smooth muscle cell migration by S1P. Gaining a better understanding of this one 
stage of angiogenesis will lead to a more complete picture of angiogenesis. This is 
important, because angiogenesis is relevant to a variety of pathogenic conditions, 
including cancer, and a better molecular understanding of this process could lead to 
future drug treatments for these disorders. 
MATERIALS AND METHODS 
Cell Culture 
Human coronary artery smooth muscle cells (Clonetics, San Diego, CA) were 
grown in culture in Dulbecco's Modified Eagle Medium (DMEM) (lnvitrogen Life 
Technologies, Rockville, MD) with 10'/0 fetal bovine serum (lnvitrogen Life 
Technologies). Human umbilical vein endothelial cells (Clonetics) were grown as 
previously described' . Cells were cultured at 37'C in a 5'/0 COq atmosphere. Cells 
&om passages 3 to 8 were used in experiments. In preparation for an experiment, cells 
were removed with trypsin-EDTA, neutralized with fetal bovine serum, centrifuged for 5 
minutes at 350 g, and resuspended in DMEM. 
Preparation and Propagation of Recombinant Adenoviruses 
Recombinant adenoviruses were constructed to express either dominant-negative 
(DN) and constitutively active (CA) forms of RhoA, Racl, Cdc42, G„in and G, iq using 
the system previously described by Vogelstein and colleagues". Construction of the DN 
Rho GTPase viruses (N17Rac 1, N17Cdc42, and N19RhoA) and the CA Rho GTPase 
viruses (V12Rac1, V12Cdc42, and V14RhoA) has been described previously . Full- 
length cDNA clones of dominant negative G subunits (G iqQ23IL/D299N and 
G iqQ226L/D294N) and constitutively active G„subunits (G„iiQ231L and G„iiQ226L) 
were obtained from Guthrie cDNA Resource Center (Sayre, PA), and prepared as the 
DN and CA Rho GTPase mutants ', using different primers and restriction 
endonucleases. The following clones were amplified using the respective primer sets: 
G~tsQ231L/D299N and G&, iiQ231L: 
GAGATCTGCCACCATGTCCGGGGTGGTGCGGACCand 
AGTCTAGATCACTGCAGCATGATGTCCTTCAG; G isQ226L/D294N and 
G„isQ226L: AGAGATCTGCCACCATGGCGGACTTCCTGCCGTCG and 
AGTCTAGATCACTGTAGCATAAGCTGCTTGAG (Genosys, The Woodlands, TX). 
Restriction digests of the PCR products of the mutant G ti and G, ts genes as well as the 
pAdTrack-CMV vector were carried out with Bglii and Xbal restriction endonucleases 
(Invitrogen Life Technologies) for 3 hours at 37'C. Digested vector and insert were 
purified, quantitated and ligated at an insert to vector ratio of 4. 5:1 overnight at 14'C' 
Positive clones were confirmed by restriction digest and colony PCR. Recombination 
and virus production were performed as previously described . When these viruses 35 
were used in experiments, cells were infected for six hours in serum-free conditions, and 
then infection was continued overnight. 
Measuring Cell Migration 
Cell migration assays were performed in a 48-well modified Boyden chamber 
(Neuroprobe, Gaithersburg, MD). Either S1P (Avanti Polar Lipids, Alabaster, AL), 
PDGF (Sigma-Aldrich), or neither was added to the lower wells, and cells at 1x10 
cells/mL were added to the upper wells. A polycarbonate membrane with 8 iim 
diameter pores (Neuroprobe), coated with 1 mg/mL gelatin and blocked with fatty acid- 
free 1 mg/mL BSA (Sigma-Aldrich) separated the wells. Experiments were performed 
in DIVIEM with 0. 4'/o reduced serum II and 10 lig/mL fibronectin (Invitrogen Life 
Technologies). Cells were allowed to migrate for four hours at 37'C in a 5'/i COz 
atmosphere. The membrane was then removed, fixed in glutaraldehyde and stained with 
amido black (30'%%d methanol, 10'/o acetic acid, 0. 1'/o naphthol blue black). The cells on 
the upper side were then removed, leaving only the cells on the lower side, which had 
migrated through the membrane. The membrane was scanned with an HP ScanJet 
5370C Scanner and then quantitated with Scion Imager. The average darkness of each 
well was measured, and the number of cells were quantitated using the equation: 
Migrated cells = 1. 1987 (darkness) + 69. 096 (darkness) 
This equation had an R value of 0. 988 (data not shown), 
Examining Cytoskeletal Morphology 
In order to examine the cytoskeletal morphology of VSMCs, cells on glass 
coverslips were stained with rhodamine-phalloidin (Molecular Probes, Eugene, OR). 
Cefls were grown to 70'/o confluency, then fixed with 3'/o paraformaldehyde for 30 
minutes. Cell membranes were permeabilized with Tx-100 and then stained with 5 
units/mL rhodamine-phalloidin for one hour. Cells were washed with PBS then 
mounted on slides and visualized using a Nikon fluorescent microscope. 
Measuring Activated RhoA 
RhoA activation was measured using a RhoA pull-down assay based on a 
previously described assay' . Before some experiments, cells were infected with virus 
overnight. Serum-free media was added to VSMCs, and then they were either lefl 
untreated or treated with 1 IiM S1P and incubated for various times at 37'C. Cells were 
washed with TBS, placed in a lysis buffer (Upstate, Lake Placid, NY), and scraped off. 
Cell lysates were centrifuged at 14, 000 g for 5 minutes. The supernatant was added to 
70 p L of Rhotekin Rho Binding Domain-bound agarose beads (Upstate) and mixed for 
45 minutes. Agarose beads were then centrifuged for 5 seconds at 10, 000 g and washed 
with lysis buffer three times. Atter a fourth centrifugation, the pellet was resuspended in 
80 trL of binding buffer containing DTT. These samples were then boiled for 10 
minutes. 
The results of the RhoA activation assay were visualized on a western blot. 
Activated GTP-RhoA samples were prepared as above. The total RhoA samples were 
prepared by taking part of the original supernatant and boiling it with binding buffer and 
P-mercapto ethanol. Samples were added to an SDS-PAGE gel, electophoresed, and 
transferred to a PVDF membrane. The membrane was then stained with mouse anti- 
RhoA (Cytoskeleton, Denver, CO) and then horseradish peroxidase-conjugated rabbit 
anti mouse (Dako Cytomation, Carpinteria, CA). Detection reagents (Amersham 
Resources, Piscataway, NJ) for chemiluminescence were added, and the membrane was 
visualized using film (Kodak). 
RESULTS 
S1P Has Contradictory Effects on Vascular Cell Migration 
The effects of SIP on different vascular cell lines were assessed using Boyden 
chamber migration assays. ECs or VSMCs were allowed to migrate for four hours 
towards SIP fmm I nM to 1000 nM in half-log doses. The results of a representative 
migration assay are shown in Figure IA. S1P strongly induced the migration of ECs. 
This effect was still increasing at the high dose of I pM. 
In contrast, SIP strongly inhibited the migration of VSMCs, completely 
abolishing their background migration. In the experiment shown, SIP inhibited VSMC 
migration even with the low dose of 10 nM, suggesting that the inhibitory effect is very 
potent (Figure IA). In some experiments, effects were observed at doses as low as 1 
nM. Because SIP exerted such opposing effects on different vascular cells, we 
performed further experiments to determine the cause of these effects. 
SIP Inhibits PDGF-Induced Migration of VSMCs 
The effect of PDGF on VSMCs was also assessed using migration assays. 
VSMCs were allowed to migrate for four hours towards PDGF from I ng/mL to 1000 
ngmL in half-log doses (Figure IB). PDGF strongly induced the migration of VSMCs. 
This effect disappeared at high concentrations, though, when the VSMCs became 
saturated. Therefore, this is a chemotactic response, dependent on the direction of a 
concentration gradient. 
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Figure 1. PDGF Induces the migration of 
VSMCs, but S1P inhibits the migration of 
VSMCs. VSMCs or ECs were seeded at 
50, 000 cells per well in the upper wells of a 
modified Boyden chamber. Cells were 
allowed to migrated for four hours through 
a gelatin-coated membrane. The cells that 
had migrated through the membrane were 
quantitated. Results here indicate the 
average +/- 1 standard deviation of three 
o o. 1 0316 1 316 ro 316 1oo wells. A) ECs or VSMCs were allowed to 
migrate towards different concentrations of 
S1P. S1P had opposite effects on the two cell types, strongly inducing EC migration but 
strongly inhibiting VSMC migration. B) VSMCs were allowed to migrate towards 
various concentrations of PDGF. PDGF strongly induced the migration of VSMCs. C) 
VSMCs were allowed to migrate toward the indicated concentrations of SIP, with or 
with out additional 32 ng/mL PDGF. S1P eliminated the increase in migration of 
VSMCs induced by PDGF. 
The ability of S1P to affect the PDGF-induced migration of VSMCs was also 
determined. VSMCs were allowed to migrate for 4 hours towards S1P from 1 nM to 
1000 nM in half-log doses, in the presence or absence of 32 ng/mL PDGF (Figure 1C). 
PDGF strongly induced the migration of VSMCs. At a dose as low as 10 nM, though, 
S1P had inhibited all migration, indicating that the inhibitory effect of S1P was 
dominant over the chemotactic effect PDGF. 
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prominent stress fibers (Figure 2B). S1P eliminated lamellipodia, pro-migratory 
structures, and induced stress fibers, stabilizing structures, correlating with its effects on 
cell migration. 
Inhibition of VSMC Migration by SIP Requires RhoA 
Since the effects of S1P on cytoskeletal morphology correlated with its effects on 
cell migration, and since the Rho GTPases play a central role in regulating cytoskeletal 
morphology ", the role of the Rho GTPases in the inhibition of VSMC migration was 
studied. The role of the Rho GTPases in inhibition of VSMC migration by S1P was 
assessed first by using dominant-negative (DN) mutants. In order to perform these 
experiments, recombinant adenoviruses carrying the gene for either a dominant-negative 
or constitutively active Rho GTPase were utilized. The preparation and characterization 
of these adenoviruses were previously described by Bayless and Davis '. After VSMCs 
were infected overnight, cells were then allowed to migrate towards 32 ng/mL PDGF, 
100 nM S1P, both, or neither for four hours (Figure 3A). The control cells, infected with 
control adenoviruses carrying only green fluorescent protein (GFP), migrated in 
response to PDGF, but S1P eliminated this migration. The cells infected with DN Rac 1 
or DN Cdc42 behaved the same as the control cells. The cells infected with DN RhoA, 
though, migrated differently. They had little response to S1P. Although S1P had a 
slight inhibitory effect in the cells shown (Figure 3A), this experiment was repeated 
multiple times, and the inhibitory effect ranged from non-existent to the slight effect 
shown here. These results demonstrate that RhoA activation is necessary for the 
inhibition of VSMC migration by S1P. 
~ I 
~l 
II ' 
I 
8 
~ 
~ 
I 
14 
The role of the Rho GTPases in inhibition of VSMC migration by S1P was also 
examined using constitutively active (CA) mutants . After VSMCs were infected 
overnight, cells were then allowed to migrate towards PDGF, S1P, both, or neither for 
four hours (Figure 3B). The cells infected with CA Cdc42 behaved the same as the 
control cells. The cells infected with CA RhoA had almost no migration, regardless of 
the presence of PDGF or S1P. The cells infected with CA Racl did not migrate as well 
as the control, with or without PDGF, but they were also not inhibited as strongly by 
S1P. These results demonstrate that RhoA activation inhibits VSMC cell migration. 
RhoA activation in response to S1P was also demonstrated directly using a RhoA 
pull-down assay. VSMCs were activated with S1P for the indicated times (Figure 3C) or 
not at all. The active GTP-bound RhoA was collected and visualized on a western blot, 
along with the total RhoA. Untreated cells showed almost no activated RhoA. 
However, immediately after treatment with S1P, RhoA was activated, and this activation 
was sustained for at least 10 minutes. These results demonstrate that S1P strongly 
activates RhoA in VSMCs. This data coupled, with our previous results showing the 
direct involvement of RhoA in S1P-induced inhibition of migration, shows that RhoA 
appears to be necessary for the inhibition of migration by S1 P. 
Inhibition of VSMC Migration by S1P Requires G 
To determine which G-protein couples the Edg receptors to RhoA to regulate 
S1P-induced inhibition of VSMC migration, we studied the role of the G„fp//3 ™y of 
G-proteins, which have been shown to signal to RhoA . The role of the G„/2/[3 family 
~ ~ tt ~ ~ 
s o 
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R 
G-proteins in this effect was investigated first using DN mutants. These mutants were 
inserted into adenoviral vectors, then introduced to VSMCs. After VSMCs were 
infected overnight, cells were allowed to migrate towards PDGF, S1P, both, or neither 
for four hours (Figure 4A). Cells infected with DN G„i q or DN RhoA were not inhibited 
as strongly by S1P. The cells infected with DN Gu/3 had lower background migration. 
S1P did not inhibit their migration as much as that of the control, but S1P did inhibit 
their migration much more than the migration of cells infected with DN G„tq or DN 
RhoA. These results indicate that activation of G„tq appears to be necessary for the 
inhibition of VSMC migration by S1P. 
The role of the Goii/i3 family G-proteins in inhibition of VSMC migration by 
S1P was also examined using CA mutants. After VSMCs were infected overnight with 
viruses carrying these mutants, cells were then allowed to migrate towards PDGF, S1P, 
both, or neither for four hours (Figure 4B). Cells infected with CA G iq or CA RhoA 
had low migration, regardless of the stimulus. The cells infected with CA G„/q migrated 
well, but did not respond positively or negatively to any stimulus. These results indicate 
that both G„~q and G„~& can contribute to activation of RhoA in VSMCs and regulate 
their migratory responses. 
The role of the Gg]i/$3 family G-proteins in activating RhoA in response to S1P 
was also examined using a RhoA pull-down assay. VSMCs were infected overnight 
with viruses containing GFP, DN G in or DN G iq. They were then either left untreated 
or activated with S1P for five minutes. The active GTP-bound RhoA was collected and 
17 
visualized on a western blot, along with the total RhoA. The two rnutants had significant 
effects on RhoA activation in response to S1P (Figure 4C). In cells infected with the 
GFP control, there was very low RhoA activation before S1P treatment, but high 
activation atter treatment. In cells infected with DN G in the increase in RhoA 
activation due to S1P was much lower. In cells infected with DN G~in though, there 
was very strong RhoA activation observed before or atter activation with S1P. These 
results indicate that G„ii activation appears to be directly involved in the activation of 
RhoA by S1P in VSMCs. 
18 
DISCUSSION AND CONCLUSIONS 
SIP is a Potent Regulator of Anglogenesls 
The results of this study support the concept that S1P is a potent regulator of 
angiogenesis. Here we demonstrate that S1P strongly induces the migration of ECs 
while inhibiting the migration of VSMCs (Figure lA). This is in contrast to the strong 
induction of VSMC migration caused by PDGF (Figure 1B), another important regulator 
of angiogenesis. From these results, a simple model of angiogenesis can be constructed 
(Figure 5). 
S1P is most important in the earlier stages of angiogenesis. In the first stage of 
angiogenesis (Figure 5B), the outer layer of an existing vessel break down, and ECs 
migrate away from the vessel. Due to its pro-migratory effects on ECs (Figure 1A), S1P 
is probably involved in this stage. S1P would be especially relevant in a wound 
environment, where the S1P concentrations would be very high, since S1P is released 
from activated platelets ' . As S1P is inducing the migration of ECs, it is inhibiting the 
migration of VSMCs. Even though PDGF, a molecule that induces the migration of 
VSMCs (Figure 1B), would also be present in this environment, our results indicated 
that the inhibitory effect of S lP overrides the pro-migratory effect of PDGF (Figure 1C). 
This would presumably prevent VSMCs from interfering with the formation of capillary 
tubes by the ECs. S1P has also been demonstrated to be involved in the morphogenesis 
of ECs into capillary tubes ' . Once these tube networks are established, VSMCs can 
migrate towards them, now without interfering with their morphogenesis (Figure 5C). 
The ECs secrete factors to draw VSMCs towards them, including PDGF' ', which 
ii:. if:, , 
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SIP Inhibits VSMC Migration by Activating G„ir and RhoA 
Because S1P has such drastic and opposing effects on different vascular cell 
types, it is important to understand the molecular basis for them. To determine which 
molecules play key roles in the inhibition of VSMC migration by S1P, we looked at 
cytoskeletal morphology in response to S I P and then molecular regulators in this 
pathway. Our results indicate that SIP inhibits VSMC migranon by activating G i2 and 
RhoA (Figure 6). 
After our initial migration assays, we observed VSMC cytoskeletal morphology 
in order to gain more insight into how S1P inhibits VSMC migration. We found that 
S1P eliminates PDGF-induced lamellipodia and induces the formation of stabilizing 
stress fibers. These results correlated with our observations of cell migration, since 
lamellipodia are structures involved in migration and stress fibers are structures involved 
in cell stabilization ' . From these results, it was clear that the Rho family of small 
GTPases may be involved in the inhibition of VSMC migration by SIP, since they are 
involved in regulating cytoskeleton morphology 
' 
. Also, RhoA is known to be 
primarily responsible for stress fiber formation, and our results clearly demonsnate 24-26 
its role in SIP-induced inhibition of VSMC migration. 
In order to determine which Rho GTPases are involved in inhibition of VSMC 
migration, we infected VSMCs with viruses carrying a gene for a DN or CA mutant of 
Rac1, Cdc42, or RhoA. The dominant-negative mutants interfere and compete with 
21 
S1P 
Edg5 
l 
RhoA ~ Migration 
Figure 6. S1P inhibits the migration of VSMCs by activating G t~ and RhoA. SIP 
activates Edg5 on the VSMC surface, which activates G iq. This initiates a signaling 
pathway inside the cell, eventually activating RhoA and inhibiting VSMC migration. 
endogenous Rho GTPases for binding to the guanosine nucleotide exchange factors 
(GEFs) that activate the GTPases by exchanging GTP for GDP. Constitutively active 
mutants prevent intrinsic GTPase-activating protein (GAP)-induced GTP hydrolysis 
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Introducing a DN mutant is the functional equivalent of removing the protein from the 
cell, and introducing a CA mutant is the functional equivalent of exaggerating the effects 
of the protein in the cell. The combination of the data from experiments with these 
elucidates the role of the native protein. 
Experiments with DN and CA mutants indicated that RhoA is necessary for 
inhibition of VSMC migration by SIP. CA RhoA inhibited VSMC migration, while S1P 
did not inhibit migration in the presence of DN RhoA. The mutants of Racl and Cdc42, 
on the other hand, did not have strong effects. In order to further confirm this 
conclusion, we performed an assay to see if RhoA is activated in response to S1P. We 
directly demonstrated RhoA activation in VSMCs in response to SIP (Figure 3C). 
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There was almost no RhoA activation before treatment with SIP, but there was strong 
activation after treatment. 
Since SIP has been shown previously to activate Edg5, a G-protein-coupled 
receptor, we then performed experiments to determine which G-protein the Edg5 
receptor activates. Since the G&, zzztz family of G-proteins has been shown to activate 
RhoA, we examined G„i z and G„i z. In order to determine which G-protein is 
involved in inhibition of VSMC migration, we infected VSMCs with viruses carrying 
the gene for DN or CA mutants of G iz and G i3 . The dominant-negative mutants 
interfere and compete with endogenous G-proteins for binding to the G-protein-coupled 
receptor responsible for activating them. Constitutively active mutants have reduced 
intrinsic GTP hydrolysis and therefore have prolonged and sustained activity for 
activating their downstream effectors. 
Experiments with DN and CAmutants indicated that, although G, iz and G iz are 
both capable of activating RhoA, G i z is necessary for inhibition of VSMC migration by 
SIP. CA G„ii inhibited VSMC migration, and CA G„iz prevented up- or down- 
regulation of migration (Figure 4A). Most importantly, though, DN G„iz, had the same 
effect as DN RhoA, preventing VSMC migration from being inhibited by SIP, but DN 
G„i z did not (Figure 4B). In order to further confirm this conclusion, a RhoA activation 
assay was performed to determine if either DN mutant affected the activation of RhoA 
by SIP (Figure 3C). Confirming the conclusion that S1P activates G„iz in VSMCs, 
leading to RhoA activation, RhoA activation was markedly lowered in cells infected 
with DN G„iz. Interestingly, though, DN G„tz markedly increased the activation of 
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RhoA, with or without SIP. This was unexpected, since DN G i3 would be expected to 
either inhibit RhoA activation if G„is is involved in the pathway or it would be expected 
to have no effect if it was not involved in the pathway. These results indicate that this 
signaling pathway is more complicated than just one protein activating another. 
Properly functioning G&, i i and G„is are both required for normal behavior of VSMCs. 
The results do, however, indicate that SIP causes activation of G~it in order to activate 
RhoA, leading to the inhibition of VSMC migration. 
Implications 
In this study, we define some of the important molecules in one stage of 
angiogenesis (i. e. the inhibition of VSMC migration). This process is important, 
because it prevents VSMCs from interfering with ECs while they form capillary tube 
networks. An understanding of all stages of angiogenesis is necessary, because 
angiogenesis is important to many life processes. Angiogenesis is an important part of 
growth, development, and healing, and if angiogenesis cannot occur, these processes will 
be severely limited. In addition, angiogenesis is involved in many pathological 
conditions. In both diabetic retinopathy, which eventually leads to blindness, and tumor 
growth, which eventually leads to cancer, unwanted angiogenesis occurs . When the 
1-3 
molecular basis of angiogenesis is fully understood, more therapeutic agents can be 
developed to directly target angiogenesis in these cases, leading to novel therapies for 
these disorders. 
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